Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Guus van Dongen"'
Autor:
Ashutosh Wechalekar, Gunnar Antoni, Wasfi Al Azzam, Mats Bergström, Swethajit Biswas, Chao Chen, Joseph Cheriyan, Matthew Cleveland, Louise Cookson, Paul Galette, Robert L. Janiczek, Raymond Y. Kwong, Mary Ann Lukas, Helen Millns, Duncan Richards, Ian Schneider, Scott D. Solomon, Jens Sörensen, James Storey, Douglas Thompson, Guus van Dongen, Danielle J. Vugts, Anders Wall, Gerhard Wikström, Rodney H. Falk
Publikováno v:
BMC Cardiovascular Disorders, Vol 22, Iss 1, Pp 1-16 (2022)
Abstract Background In a Phase I study treatment with the serum amyloid P component (SAP) depleter miridesap followed by monoclonal antibody to SAP (dezamizumab) showed removal of amyloid from liver, spleen and kidney in patients with systemic amyloi
Externí odkaz:
https://doaj.org/article/a733adacf3434f19a23e0e826ad2a704
Autor:
Kevin S. Thorneloe, Armin Sepp, Sean Zhang, Laura Galinanes-Garcia, Paul Galette, Wasfi Al-Azzam, Danielle J. Vugts, Guus van Dongen, Phillip Elsinga, Johan Wiegers, Andor W. J. M. Glaudemans, Veena Vincent, Jessica Renaux, Matt Szapacs, Mary Birchler, Matthew Cleveland, Mats Bergstrom, Marie Davies
Publikováno v:
EJNMMI Research, Vol 9, Iss 1, Pp 1-12 (2019)
Abstract Conjugation or fusion to AlbudAbs™ (albumin-binding domain antibodies) is a novel approach to extend the half-life and alter the tissue distribution of biological and small molecule therapeutics. To understand extravasation kinetics and ex
Externí odkaz:
https://doaj.org/article/eba10547950944e2b456a3b51b283abc
Autor:
Christian Klein, Inja Waldhauer, Valeria G. Nicolini, Anne Freimoser-Grundschober, Tapan Nayak, Danielle J. Vugts, Claire Dunn, Marije Bolijn, Jörg Benz, Martine Stihle, Sabine Lang, Michaele Roemmele, Thomas Hofer, Erwin van Puijenbroek, David Wittig, Samuel Moser, Oliver Ast, Peter Brünker, Ingo H. Gorr, Sebastian Neumann, Maria Cristina de Vera Mudry, Heather Hinton, Flavio Crameri, Jose Saro, Stefan Evers, Christian Gerdes, Marina Bacac, Guus van Dongen, Ekkehard Moessner, Pablo Umaña
Publikováno v:
OncoImmunology, Vol 6, Iss 3 (2017)
We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembry
Externí odkaz:
https://doaj.org/article/a319ded80cfa47ca96224b37437a82ff
Autor:
Flavio M. Gripp, Jasper Quak, Hein Leverstein, Ad Schrijvers, Martijn Gerretsen, Ruud Brakenhoff, Guus Van Dongen, Gordon B. Snow, Abrão Rapoport
Publikováno v:
São Paulo Medical Journal, Vol 112, Iss 3, Pp 612-621
O grupo de carcinomas espinocelulares da cabeça e pescoço em pacientes com alto risco de desenvolver metástases à distância, tem sido bem definidos do ponto de vista prognóstico em nossa instituição. Com intuito de selecionar fatores de risco
Externí odkaz:
https://doaj.org/article/9770db92ab0f4e389cffe4b2f82241a9
Publikováno v:
Högnäsbacka, A, Poot, A J, Vugts, D J, van Dongen, G A M S & Windhorst, A D 2022, ' The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor ', Pharmaceuticals, vol. 15, no. 4, 450 . https://doi.org/10.3390/ph15040450
Multiple small molecule PET tracers have been developed for the imaging of the epidermal growth factor receptor (EGFR). These tracers target the tyrosine kinase (TK) domain of the receptor and have been used for both quantifying EGFR expression and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dd06ad7b19097c1136672414e61fec6
https://research.vumc.nl/en/publications/1a80a8a7-40e3-4b51-a96f-545f664f13bc
https://research.vumc.nl/en/publications/1a80a8a7-40e3-4b51-a96f-545f664f13bc
Autor:
Antonia Högnäsbacka, Alex Poot, Christophe Plisson, Jonas Bergare, Stuart McCluskey, David Bonsall, Lisa Wells, Esther Kooijman, Robert Schuit, Mariska Verlaan, Wissam Beaino, Guus van Dongen, Danielle Vugts, Charles Elmore, Jan Passchier, Albert Windhorst
Publikováno v:
Nuclear Medicine and Biology. :S38-S39
Autor:
Thomas Wuensche, Natascha Stergiou, Iris Mes, Mariska Verlaan, Maxime Schreurs, Esther Kooijman, Bart Janssen, Albert Windhorst, Soren Christensen, Allan Jensen, Ayodeji Asuni, Benny Bang-Andersen, Wissam Beaino, Guus van Dongen, Danielle Vugts
Publikováno v:
Nuclear Medicine and Biology. :S24
Autor:
Dasa Lipovsek, Idris Bahce, N.H. Hendrikse, Danielle J. Vugts, G.A.M.S. (Guus) van Dongen, Alex J. Poot, Anna-Larissa N. Niemeijer, Egbert F. Smit, T.D. de Gruijl, Marc C. Huisman, Ronald Boellaard, David J. Donnelly, Ralph Adam Smith, Erik Thunnissen, Wendy Hayes, Linda M. Velasquez, David Leung, Albert D. Windhorst, Shuyan Du, A.J. de Langen, Samuel J. Bonacorsi, Otto S. Hoekstra, Paul E. Morin
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-5 (2018)
Niemeijer, A N, Leung, D, Huisman, M C, Bahce, I, Hoekstra, O S, van Dongen, G A M S, Boellaard, R, Du, S, Hayes, W, Smith, R, Windhorst, A D, Hendrikse, N H, Poot, A, Vugts, D J, Thunnissen, E, Morin, P, Lipovsek, D, Donnelly, D J, Bonacorsi, S J, Velasquez, L M, de Gruijl, T D, Smit, E F & de Langen, A J 2018, ' Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer ', Nature Communications, vol. 9, no. 1, 4664 . https://doi.org/10.1038/s41467-018-07131-y
Nature Communications
Nature Communications, 9(1):4664. Nature Publishing Group UK
Niemeijer, A N, Leung, D, Huisman, M C, Bahce, I, Hoekstra, O S, van Dongen, G A M S, Boellaard, R, Du, S, Hayes, W, Smith, R, Windhorst, A D, Hendrikse, N H, Poot, A, Vugts, D J, Thunnissen, E, Morin, P, Lipovsek, D, Donnelly, D J, Bonacorsi, S J, Velasquez, L M, de Gruijl, T D, Smit, E F & de Langen, A J 2018, ' Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer ', Nature Communications, vol. 9, no. 1, 4664 . https://doi.org/10.1038/s41467-018-07131-y
Nature Communications
Nature Communications, 9(1):4664. Nature Publishing Group UK
PD-L1 immunohistochemistry correlates only moderately with patient survival and response to PD-(L)1 treatment. Heterogeneity of tumor PD-L1 expression might limit the predictive value of small biopsies. Here we show that tumor PD-L1 and PD-1 expressi
Autor:
Marc Huisman, Ignacio Melero, Oliver Krieter, Ronald Boellaard, Florian Heil, María José García Velloso, Camilla Matheisen, Guus van Dongen, Iván Peñuelas, Radoiane Helbaj, Maria E. Rodriguez-Ruiz, Mariano Ponz-Sarvise, Maurizio Ceppi, Danielle Vugts, Michael Hettich, Ernesto Guarin, Francois Iglesias, Marta Cañamero, Miguel F. Sanmamed
Publikováno v:
Regular and young investigator award abstracts.
Background RO7122290 (RO) is a potent next generation 4-1BB agonist simultaneously targeting fibroblast activation protein (FAP). FAP is highly expressed on cancer-associated fibroblasts in many solid tumors, while expression in healthy tissue is low
Autor:
E. J. van Helden, E.G.E. de Vries, Sjoerd G. Elias, N.C.T. van Grieken, C.M.L. van Herpen, S. C. van Es, D.J. Vugts, Ronald Boellaard, C. W. Menke-van der Houven van Oordt, Wim J.G. Oyen, H. M. W. Verheul, Otto S. Hoekstra, M. C. Huisman, Sophie L. Gerritse, G.A.M.S. (Guus) van Dongen, Eline Boon, Henk L. Dekker, Adrienne H. Brouwers
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging, 47, 4, pp. 849-859
European Journal of Nuclear Medicine and Molecular Imaging, 47(4), 849-859. Springer Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 47, 849-859. SPRINGER
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 47(4), 849. Springer Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 47, 849-859
van Helden, E J, Elias, S G, Gerritse, S L, van Es, S C, Boon, E, Huisman, M C, van Grieken, N C T, Dekker, H, van Dongen, G A M S, Vugts, D J, Boellaard, R, van Herpen, C M L, de Vries, E G E, Oyen, W J G, Brouwers, A H, Verheul, H M W, Hoekstra, O S & Menke-van der Houven van Oordt, C W 2020, ' [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. 4, pp. 849-859 . https://doi.org/10.1007/s00259-019-04555-6
European Journal of Nuclear Medicine and Molecular Imaging, 47(4), 849-859. Springer Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 47, 849-859. SPRINGER
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 47(4), 849. Springer Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 47, 849-859
van Helden, E J, Elias, S G, Gerritse, S L, van Es, S C, Boon, E, Huisman, M C, van Grieken, N C T, Dekker, H, van Dongen, G A M S, Vugts, D J, Boellaard, R, van Herpen, C M L, de Vries, E G E, Oyen, W J G, Brouwers, A H, Verheul, H M W, Hoekstra, O S & Menke-van der Houven van Oordt, C W 2020, ' [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. 4, pp. 849-859 . https://doi.org/10.1007/s00259-019-04555-6
Purpose One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [89Zr]Zr-cet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::649e8819f0b3fb0a2350dc60b8a96a2f
https://hdl.handle.net/2066/219439
https://hdl.handle.net/2066/219439